SAINT LAURENT, Quebec, Nov. 09, 2022 (GLOBE NEWSWIRE) — IntelGenx Corp. IGX IGXT (the “Company” or “IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a Feasibility Study & Development Agreement (the “Agreement”) with an undisclosed animal health company focused on advancing a VetaFilm™-based oral film formulation containing CBD for use in companion animals.
Pursuant to the Agreement, IntelGenx will provide a CBD-infused VetaFilm™ product prototype for clinical investigation. Based on successful feasibility, IntelGenx will enter into negotiations for a commercial agreement, pursuant to which IntelGenx will have exclusive rights to further develop, manufacture and supply the developed product.
“This agreement marks yet another important first for us within the animal health space,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “We are looking forward to working to make CBD-infused VetaFilm™ products available within the global CBD pet market, which is expected to grow at a compound annual growth rate of 58.9% to reach $4.79 billion by 2028.”
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.